Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Former Detroit Lions players announce partnership with Harvard to study marijuana

Former Detroit Lions football players Calvin Johnson and Robert Sims are expanding their emerging cannabis enterprise into the field of medicine. The pair announced an agreement Thursday with the International Phytomedicines and Medical Cannabis Institute at Harvard University, which is researching the benefits of medical marijuana and looking at the best ways to deliver cannabis-based…
Read More

Updated Arfinn Med Scheduler

As your practice begins to grow, it’s important that your booking system is able to keep up.  That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform.  This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More

Medical marijuana users tell their stories to Medical Cannabis Study Commission

Thursday, the Medical Cannabis Study Commission held its third meeting. The Commission has been tasked with presenting a policy recommendation to the legislature on exactly what the best medical marijuana bill should look like. The Commission held a public hearing in which a number of medical marijuana users claimed that the drug has benefitted them.…
Read More

Doctors and patients are flying blind as medical marijuana use rises, research lags

Marijuana’s role in the health care universe has grown exponentially over the past few years. Currently, 33 U.S. states have legalized the use of medical marijuana, and more and more states are considering making it legal for recreational purposes as well. As cannabis becomes more accessible, many people are turning to tetrahydrocannabinol (THC) and cannabidiol (CBD) products to…
Read More

Combating Opioid Dependence

The opioid epidemic is a hot topic across the United States, along with the alternatives that could alleviate the tragic consequences the epidemic brings. Opioids, also known as narcotics, are strong prescription pain relievers such as oxycodone, hydrocodone and fentanyl. Although illegal, heroin is also considered to be an opioid. Most patients are introduced to…
Read More

LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY

There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed. Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed…
Read More

Leave a Comment

You must be logged in to post a comment.